Dopamine D2/D3 receptor binding of [123I]epidepride in risperidone-treatment chronic MK-801-induced rat schizophrenia model using nanoSPECT/CT neuroimaging

Nuclear Medicine and Biology

Volumn 41, Issue 8, 2014, Pages 681-687

  Huang, Y R ^a   Pai, C W ^a   Cheng, K H ^a   Kuo, W I ^a   Chen, M W ^a   Chang, K W ^a  

^a INSTITUTE OF NUCLEAR ENERGY RESEARCH   (Taiwan)

Author keywords

Epidepride; MK 801; Rat model; Risperidone; Schizophrenia

Indexed keywords

DIZOCILPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; EPIDEPRIDE I 123; RADIOPHARMACEUTICAL AGENT; RISPERIDONE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE; DIZOCILPINE MALEATE; DOPAMINE RECEPTOR; EPIDEPRIDE; PROTEIN BINDING; PYRROLIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; CT SPECT SCANNER; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; MALE; MESENCEPHALON; NEUROIMAGING; NONHUMAN; PSYCHOSOCIAL WITHDRAWAL; RAT; RECEPTOR BINDING; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOCIAL INTERACTION; ANIMAL; CHEMICALLY INDUCED; CHRONIC DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; DISEASE MODEL; METABOLISM; MULTIMODAL IMAGING; SPRAGUE DAWLEY RAT;

ANIMALS; BENZAMIDES; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; MALE; MULTIMODAL IMAGING; NEUROIMAGING; PROTEIN BINDING; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RISPERIDONE; SCHIZOPHRENIA; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; TYROSINE 3-MONOOXYGENASE;

EID: 84904430329     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2014.04.133     Document Type: Article

References (53)

1. Miyamoto S., Duncan G.E., Marx C.E., Lieberman J.A. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2005, 10(1):79-104.
2. 3 receptor in chronic MK-801-induced rat schizophrenia model. Nucl Med Biol 2012, 39(6):826-832.
3. Kalkman H.O., Loetscher E. GAD(67): the link between the GABA-deficit hypothesis and the dopaminergic- and glutamatergic theories of psychosis. J Neural Transm 2003, 110(7):803-812.
4. Bubeníková-Valesová V., Horácek J., Vrajová M., Höschl C. Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. Neurosci Biobehav Rev 2008, 32(5):1014-1023.
5. Weinberger D.R. Implications of the normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987, 44:660-669.
6. Reith J., Benkenfat C., Sherwin A., Yasuhara Y., Kuwabara H., Andermann F., et al. Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci U S A 1994, 91:11651-11654.
7. Finlay J.M. Mesoprefrontal dopamine neurons and schizophrenia: role of developmental abnormalities. Schizophr Bull 2001, 27:431-442.
8. Sams-Dodd F. Phencyclidine in the social interaction test: an animal model of schizophrenia with face and predictive validity. Rev Neurosci 1999, 10:59-90.
9. 2/3 receptor agonists in mice. Pharmacol Biochem Behav 2004, 77:309-318.
10. Kalinichev M., Robbins M.J., Hartfield E.M., Maycox P.R., Moore S.H., Savage K.M., et al. Comparison between intraperitoneal and subcutaneous phencyclidine administration in Sprague-Dawley rats: a locomotor activity and gene induction study. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:414-422.
11. Rung J.P., Carlsson A., Rydén Markinhuhta K., Carlsson M.L. (+)-MK-801 induced social withdrawal in rats; a model for negative symptoms of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29:827-832.
12. Roenker N.L., Gudelsky G., Ahlbrand R., Bronson S.L., Kern J.R., Waterman H., et al. Effect of paliperidone and risperidone on extracellular glutamate in the prefrontal cortex of rats exposed to prenatal immune activation or MK-801. Neurosci Lett 2011, 500(3):167-171.
13. Jentsch J.D., Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1999, 20:201-225.
14. Bubeníková V., Votava M., Horácek J., Pálenícek T., Dockery C. The effect of zotepine, risperidone, clozapine and olanzapine on MK-801-disrupted sensorimotor gating. Pharmacol Biochem Behav 2005, 80:591-596.
15. Castellano O., Moscoso A., Riolobos A.S., Carro J., Arji M., Molina V., et al. Chronic administration of risperidone to healthy rats: a behavioural and morphological study. Behav Brain Res 2009, 205(2):488-498.
16. Nandra K.S., Agius M. The differences between typical and atypical antipsychotics: the effects on neurogenesis. Psychiatr Danub 2012, 24(Suppl. 1):S95-S99.
17. Harvey P.D., Green M.F., Keefe R.S., Velligan D.I. Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. J Clin Psychiatry 2004, 65(3):361-372.
18. 2 dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. Br J Psychiatry 2001, 179:503-508.
19. 2 dopamine receptor occupancy in the living human brain. A PET study with risperidone. Psychopharmacology (Berl) 1993, 110:265-272.
20. Leucht S., Corves C., Arbter D., Engel R.R., Li C., Davis J.M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 373(9657):31-41.
21. Kumari V., Soni W., Sharma T. Prepulse inhibition of the startle response in risperidone-treated patients: comparison with typical antipsychotics. Schizophr Res 2002, 55(1-2):139-146.
22. Richtand N.M., Taylor B., Welge J.A., Ahlbrand R., Ostrander M.M., Burr J., et al. Risperidone pretreatment prevents elevated locomotor activity following neonatal hippocampal lesions. Neuropsychopharmacology 2006, 31:77-89.
23. Piontkewitz Y., Arad M., Weiner I. Risperidone administered during asymptomatic period of adolescence prevents the emergence of brain structural pathology and behavioral abnormalities in an animal model of schizophrenia. Schizophr Bull 2011, 37(6):1257-1269.
24. Celikyurt I.K., Akar F.Y., Ulak G., Mutlu O., Erden F. Effects of risperidone on learning and memory in naive and MK-801-treated rats. Pharmacology 2011, 87(3-4):187-194.
25. Stojković T., Radonjić N.V., Velimirović M., Jevtić G., Popović V., Doknić M., et al. Risperidone reverses phencyclidine induced decrease in glutathione levels and alterations of antioxidant defense in rat brain. Prog Neuropsychopharmacol Biol Psychiatry 2012, 39(1):192-199.
26. Murray R.M., Lappin J., Di Forti M. Schizophrenia: from developmental deviance to dopamine dysregulation. Eur Neuropsychopharmacol 2008, 18(Suppl. 3):S129-S134.
27. Schmitt G.J., Meisenzahl E.M., Frodl T., La Fougère C., Hahn K., Möller H.J., et al. Increase of striatal dopamine transmission in first episode drug-naive schizophrenic patients as demonstrated by [(123)I]IBZM SPECT. Psychiatry Res 2009, 173(3):183-189.
28. 2 receptor binding in the anterior cingulate cortex in schizophrenia. Arch Gen Psychiatry 2002, 59:25-30.
29. 2/3 receptor density and distribution in drug-nair̈ve schizophrenic patients. Mol Psychiatry 2003, 8:453-455.
30. 11C]FLB 457. Int J Neuropsychopharmacol 2003, 6:361-370.
31. Shergill S.S., Brammer M.J., Williams S.C., Murray R.M., McGuire P.K. Mapping auditory hallucinations in schizophrenia using functional magnetic resonance imaging. Arch Gen Psychiatry 2000, 57:1033-1038.
32. 2/3 receptor binding in schizophrenia. Eur Arch Psychiatry Clin Neurosci 2006, 256:382-387.
33. 3 receptor and transporter binding in drug-naive patients with schizophrenia: a dual-isotope SPECT study. Am J Psychiatry 2004, 161(8):1496-1498.
34. Castellani S., Adams P.M. Acute and chronic phencyclidine effects on locomotor activity, stereotypy and ataxia in rats. Eur J Pharmacol 1981, 73(2-3):143-154.
35. Sturgeon R.D., Fessler R.G., London S.F., Meltzer H.Y. Behavioural effectsof chronic phenyclidine administration in rats. Psychopharmacology (Berl) 1982, 76:52-56.
36. Jentsch J.D., Redmond D.E., Elsworth J.D., Taylor J.R., Younren K.D., Roth R.H. Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science 1997, 277:953-955.
37. Jentsch J.D., Tran A., Le D., Youngren K.D., Roth R.H. Sub-chronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat. Neuropsychopharmacology 1997, 17:92-99.
38. Xu X., Domino E.F. Phencyclidine-induced behavioural sensitization. Pharmacol Biochem Behav 1994, 47:603-608.
39. Hadjiconstantinou M., Rossetti Z.L., Wemlinger T.A., Neff N.H. Dizocilpine enhances striatal tyrosine hydroxylase and aromatic l-amino acid decarboxylase activity. Eur J Pharmacol 1995, 289:97-101.
40. Biggs C.S., Fowler L.J., Whitton P.S., Starr M.S. NMDA receptor antagonists increase the release of dopamine in the substantia nigra of reserpine-treated rats. Eur J Pharmacol 1996, 299:83-91.
41. Mathé J.M., Nomikos G.G., Blakeman K.H., Svensson T.H. Differential actions of dizocilpine (MK-801) on the mesolimbic and mesocortical dopamine systems: role of neuronal activity. Neuropharmacology 1999, 38:121-128.
42. Gandolfi O., Dall'Olio R. Chronic treatment with MK-801 decreases D2 dopamine receptor function in rat striatum. Pharmacol Biochem Behav 1993, 44(3):683-687.
43. Tarazi F.I., Florijn W.J., Creese I. Differential regulation of dopamine receptors after chronic typical and atypical antipsychotic drug treatment. Neuroscience 1997, 78(4):985-996.
44. Ginovart N., Wilson A.A., Hussey D., Houle S., Kapur S. D2-receptor upregulation is dependent upon temporal course of D2-occupancy: a longitudinal [11C]-raclopride PET study in cats. Neuropsychopharmacology 2009, 34(3):662-671.
45. Lee T., Seeman P., Tourtellotte W.W., Farley I.J., Hornykeiwicz O. Binding of 3H-neuroleptics and 3H-apomorphine in schizophrenic brains. Nature 1978, 274(5674):897-900.
46. Mackay A.V., Iversen L.L., Rossor M., Spokes E., Bird E., Arregui A., et al. Increased brain dopamine and dopamine receptors in schizophrenia. Arch Gen Psychiatry 1982, 39(9):991-997.
47. Kusumi I1., Takahashi Y., Suzuki K., Kameda K., Koyama T. Differential effects of subchronic treatments with atypical antipsychotic drugs on dopamine D2 and serotonin 5-HT2A receptors in the rat brain. J Neural Transm 2000, 107(3):295-302.
48. Samaha A.N., Seeman P., Stewart J., Rajabi H., Kapur S. "Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci 2007, 27(11):2979-2986.
49. 2A/2C receptors. Eur J Pharmacol 2007, 564(1-3):123-130.
50. Sams-Dodd F. The effects of novel antipsychotic drugs on PCP-induced stereotyped behaviour and social isolation in the rat social interaction test. Behav Pharmacol 1997, 8:196-215.
51. Van Beijsterveldt L.E., Geerts R.J., Leysen J.E., Megens A.A., Van den Eynde H.M., Meuldermans W.E., et al. Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. Psychopharmacology (Berl) 1994, 114(1):53-62.
52. Ichikawa J., Ishii H., Bonaccorso S., Fowler W.L., O'Laughlin I.A., Meltzer H.Y. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 2001, 76(5):1521-1531.
53. Verma V., Lim E.P., Han S.P., Nagarajah R., Dawe G.S. Chronic high-dose haloperidol has qualitatively similar effects to risperidone and clozapine on immediate-early gene and tyrosine hydroxylase expression in the rat locus coeruleus but not medial prefrontal cortex. Neurosci Res 2007, 57(1):17-28.